(2R,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol is an impurity of Tetrabenazine, which is a VMAT inhibitor used in the treatment of hyperkinetic movement disorder.

Binospirone (MDL 73005EF) is a 5-HT1A receptor agonist with anxiolytic activity used in the study of glaucoma and movement disorders associated with neurologic dysfunction.

RWJ-51204 is a selective adenosine A2A receptor antagonist and a partial agonist of GABA(A) receptor (IC50: 0.2-2 nM). It has neuroprotective and movement-improving effects and can be used in research related to Parkinson's disease.

Sarizotan 2HCl is an hERG channel inhibitor and 5-hydroxytryptamine 5-HT1A receptor agonist with potential antidepressant effects for the study of Parkinsonian movement disorders.

Anpirtoline hydrochloride (D-16949 hydrochloride) is a novel and potent 5-HT1B receptor agonist and 5-HT3 receptor antagonist with anti-injurious, analgesic, and antidepressant activity, and is used in the study of movement disorders.

SB 243213 is an orally available and selective 5-HT2C receptor antagonist.SB 243213 has anxiolytic and antidepressant activity and is used in schizophrenia and movement disorders.

MFN2 agonist-1 (B-A/l) effectively induces mitochondrial fusion in cells deficient in mitofusin 2 (MFN2). It counteracts mitochondrial clumping (formation of static mitochondrial aggregates) and reinstates mitochondrial movement in cultured mouse neurons harboring the CMT2A-associated MFN2 T105M mutation.

YH16899 is a KRS-67LR interaction inhibitor by directly blocking the association between KRS and 67LR, suppressing the dynamic movement of the N-terminal extension of KRS and reducing membrane localization of KRS.

Lacinilene C, lacinilene C 7-methyl ether, scopoletin, 2-hydroxy-7-methoxycadalene and 2,7-dihydroxycadalene are 5 induced phytoalexins in cotton leaves. Lacinilene C methyl ether elicits contraction of TSM by enhancing the movement of calcium through pot

Rimtuzalcap (CAD-1883) (CAD-1883), a pioneering selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels), is employed in the study of movement disorders such as spinocerebellar ataxia (SCA) and essential tremor (ET).

E70K is a compound that inhibits the interaction between the chemokine (C-X-C) ligand 8 (CXCL8) and glycosaminoglycans (GAGs) on cell membrane surfaces. It mimics a segment of the CXCL8 protein's GAG-binding region at the C-terminal end, incorporating a glutamate-to-lysine mutation at the 70th position. At a concentration of 50 nM, E70K notably reduces the attachment of primary human neutrophils to human umbilical vein endothelial cells (HUVECs). Moreover, it impedes the CXCL8-triggered movement of these neutrophils across HMEC-1 human microvascular endothelial cell layers within a concentration range of 1 to 1,000 nM.

CVN417 is an orally active antagonist of nAChR containing the α6 subunit, modulating phasic dopaminergic neurotransmission in an impulse-dependent fashion. It inhibits Ca(2+) efflux through nAChR subunits, displaying IC50 values of 0.086 μM (α6), 2.56 μM (α3), and 0.657 μM (α4). CVN417 has shown efficacy in reducing resting tremor in rodent models, suggesting a potential to ameliorate movement disorders in conditions like Parkinson's disease [1].

20-HC-Me-Pyrrolidine was A potent inhibitor of Aster protein, with IC50 values of 0.11 μM, 0.06 μM and 0.71 μM for Aster A, Aster B and Aster C, respectively. 20-HC-Me-Pyrrolidine prevents Aster protein from binding and transferring cholesterol and inhibits the movement of low-density lipoprotein (LDL) cholesterol into the endoplasmic reticulum (ER).

ABD459 is a neutral antagonist of the central cannabinoid 1 (CB1) receptor (Ki = 8.6 nM). It inhibits food consumption in nonfasted mice without affecting motor activity. ABD459 reduces active food seeking for 5-6 hours after treatment, with no rebound after washout. ABD459 also diminishes rapid eye movement (REM) sleep, with no alterations of wakefulness or non-REM sleep.

Deanol acetamidobenzoate is CNS stimulant. It can be caused elevated blood choline levels, can be used in Treatment of Choreiform Movement Disorders.

Eliprodil (SL-820715)(SL-820715), a non-competitive NR2B-NMDA receptor antagonist(IC50: 1 uM), less effective for NR2A- and NR2C-containing receptors(IC50> 100 uM). It has been used in trials studying the treatment of Parkinson Disease and Movement Disorders.

CK-666 is a cell-permeable inhibitor of actin-related protein Arp2/3 complex. It binds to the Arp2/3 complex, stabilizes the inactive state of the complex, blocking the movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch)

Tetrabenazine D6 is the deuterium-labeled Tetrabenazine. Tetrabenazine is a VMAT-inhibitor used for the treatment of hyperkinetic movement disorder.

Taminadenant is an adenosine receptor antagonist.

Cannabidiolic acid (CBDA), the predominant phytocannabinoid in fiber and seed-oil hemp (Cannabis sativa L.), exhibits a range of biological activities, including the inhibition of vomiting induced by toxins or motion sickness and the enhancement of 5-HT1A receptor activation in the rat brain stem membrane. It offers a more potent effect than cannabidiol in reducing emetic responses and delaying the onset of emesis in rats exposed to movement. Additionally, CBDA holds potential as an anti-inflammatory, anxiolytic, and antidepressant agent.

Sanguiin h 11 is a compound purified from the plant Sanguisorba officinalis and has proven to be a potent inhibitor of chemoattractant-dependent and independent neutrophil movement.

Maribavir (GW257406X) is an orally available benzimidazole riboside compound with activity against cytomegalovirus (CMV). Maribavir is a selective ATP competitor of the viral UL97 kinase, which is involved in viral nuclear maturation events, such as viral DNA assembly and movement of viral capsids from the nucleus of infected cells. Maribavir has activity against strains of CMV that are resistant to standard anti-CMV agents.

Tetrabenazine (Ro 1-9569) is a drug formerly used as an antipsychotic and treatment of various movement disorders. Tetrabenazine blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system.

Tat-QFNP12 is a peptide that combines a transcriptional transactivator (Tat) transmembrane domain with an inhibitor targeting the interaction between N-Myc downstream regulated gene 2 (NDRG2) and protein phosphatase Mg2+/Mn2+ dependent 1A (PPM1A). This compound effectively mitigates blood-brain barrier endothelial tight junction disruption caused by elevated levels of matrix metalloproteinase-9 (MMP-9), alleviates cerebral edema, and promotes spontaneous activity along with symmetric limb movement in a mouse model of subarachnoid hemorrhage induced by endovascular puncture. These benefits are observed at a dosage of 20 mg/kg.

12-Hydroxyjasmonic acid glucoside is a COI1-JAZ-independent activator of leaf-closing movement in samanea saman.

NaV1.2/1.6 channel blocker-1 is a potent NaV1.2/1.6 channel blocker with inhibitory effects on rNaV1.6 and hNaV1.2.NaV1.2 channel blocker-1 can be used in the study of generalised epilepsy and movement disorders.

c-Met-IN-10 is a potent c-Met kinase inhibitor (IC50: 16 nM). c-Met-IN-10 inhibits the activity of cancer cells A549, H460 and HT-29, and inhibits A549 cell movement by inhibiting HT-29 cell colony formation, which in turn induces apoptosis in HT-29 and A549 cells. c-Met-IN-10 can be used in anticancer studies. -Met-IN-10 is capable of being used in anticancer studies.

Tetrabenazine methanesulfonate is a medicine formerly utilized as an antipsychotic and therapy for various movement disorders. Tetrabenazine methanesulfonate blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high-affin

Azeliragon is a potent and orally active inhibitor of RAGE (receptor for advanced glycation endproducts), a pattern recognition receptor, which affects the movement of amyloid, an Alzheimer's-associated protein, into the brain.

Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity.

Fluphenazine decanoate is dopamine D2 receptor blocke,and is a long-acting phenothiazine neuroleptic that used to treat schizophrenia.

Seltorexant (JNJ-42847922) crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain. Seltorexant is a high-affinity and selective orexin-2 receptor antagonist (pKi: 8.0 and 8.1 for human and rat OX2R).

(+)-Tetrabenazine ((3R,11bR)-Tetrabenazine) is a reversible vesicular monoamine transporter 2 (VMAT-2) inhibitor, inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.

Tetrabenazine Racemate (Rubigen) is a selective and reversible inhibitor of vesicular monoamine transporter-2 (VMAT-2). Tetrabenazine Racemate blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high-affinity label for the vesicle transport system.